Stock Events

Stock Events

Synairgen 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-8.14MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is involved in the development of respiratory treatments, including cystic fibrosis therapies, which could compete with Synairgen's respiratory disease treatments.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences has a broad portfolio of treatments for viral and respiratory diseases, potentially competing with Synairgen's COVID-19 and other respiratory disease treatments.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca has a strong focus on respiratory and immunology, including treatments for asthma and COPD, which could compete with Synairgen's respiratory therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is involved in the development of treatments for respiratory syncytial virus (RSV) and other lung diseases, competing with Synairgen's respiratory focus.
Merck
MRK
Mkt Cap368.89B
Merck & Co. has a diverse drug portfolio that includes treatments for infectious diseases, potentially competing with Synairgen's development of treatments for viral-induced respiratory diseases.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad range of treatments for infectious and respiratory diseases, including COVID-19 vaccines and treatments, competing with Synairgen's respiratory disease focus.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on advanced therapies for serious diseases, including potential treatments for lung diseases, which could compete with Synairgen's respiratory disease treatments.
Novartis
NVS
Mkt Cap303.67B
Novartis has a strong presence in the respiratory market, including treatments for asthma and COPD, competing with Synairgen's focus on respiratory diseases.
Sanofi
SNY
Mkt Cap106.24B
Sanofi is involved in the development of treatments for respiratory conditions and infectious diseases, potentially competing with Synairgen's focus on respiratory diseases.

About

Synairgen plc is a biopharmaceutical company focused on the discovery and advancement of therapeutic drugs for various respiratory conditions. Their product pipeline features SNG001, an inhaled interferon beta under development for the treatment of COVID-19. They are also conducting Phase II clinical trials for an inhaled formulation of interferon beta (IFN-ß), targeting both asthma exacerbated by the common cold and flu, and the treatment or prevention of chronic obstructive pulmonary disease (COPD). Furthermore, Synairgen is developing a LOXL2 inhibitor specifically for idiopathic pulmonary fibrosis (IPF) disease. This LOXL2 inhibitor is being developed through a licensing and collaborative agreement with Pharmaxis Ltd. The company was founded in 2004 and is based in Southampton, United Kingdom.
Show More
CEO
Joseph Tregonning Colliver
Employees
34
Country
United Kingdom
ISIN
GB00B0381Z20
WKN
000A0DK7J

Listings

MU
DE
OMY.MU
STU
DE
OMY.STU
OTC Link
US
SYGGF

0 Comments

Share your thoughts

FAQs

What is Synairgen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Synairgen stocks are traded under the ticker OMY.STU.
What is Synairgen revenue for the last year?▼
Synairgen revenue for the last year amounts to 0 EUR.
What is Synairgen net income for the last year?▼
OMY.STU net income for the last year is -8.14M EUR.
How many employees does Synairgen have?▼
As of November 2, 2026, the company has 34 employees.
In which sector is Synairgen located?▼
Synairgen operates in the Health & Wellness sector.
When did Synairgen complete a stock split?▼
Synairgen has not had any recent stock splits.
Where is Synairgen headquartered?▼
Synairgen is headquartered in Southampton, United Kingdom.